Clinical breast cancer
-
Clinical breast cancer · Aug 2010
Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.
Trastuzumab (Herceptin; Genentech, Inc.; South San Francisco, CA) provides clinical benefit when combined with chemotherapy or as monotherapy in patients with HER2-positive metastatic breast cancer (MBC). Given the demonstrated improvement in standard outcomes, it is important to assess this therapy's effect on patients' health-related quality of life (HRQOL). ⋯ Trastuzumab has a beneficial effect on HRQOL in patients with HER2-positive MBC, particularly those with responsive disease.